Royal Bank of Canada
CNCR

Royal Bank of Canada’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Royal Bank of Canada’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-82
Closed -$1K – 7061
2025
Q1 		$1K Sell
82
-227
-73% -$2.65K ﹤0.01% 6642
2024
Q4 		$4K Buy
309
+244
+375% +$3.45K ﹤0.01% 6570
2024
Q3 		$1K Sell
65
-20,045
-100% -$295K ﹤0.01% 6692
2024
Q2 		$272K Buy
20,110
+9,722
+94% +$144K ﹤0.01% 4508
2024
Q1 		$173K Sell
10,388
-973
-9% -$15K ﹤0.01% 4810
2023
Q4 		$153K Buy
11,361
+6,236
+122% +$68.1K ﹤0.01% 5312
2023
Q3 		$56K Sell
5,125
-26,693
-84% -$326K ﹤0.01% 5715
2023
Q2 		$411K Buy
31,818
+13,403
+73% +$176K ﹤0.01% 4101
2023
Q1 		$221K Sell
18,415
-3,194
-15% -$43.5K ﹤0.01% 4535
2022
Q4 		$297K Buy
21,609
+7,773
+56% +$114K ﹤0.01% 4543
2022
Q3 		$203K Buy
13,836
+7,658
+124% +$124K ﹤0.01% 4761
2022
Q2 		$94K Buy
6,178
+528
+9% +$8.09K ﹤0.01% 5368
2022
Q1 		$102K Sell
5,650
-16,857
-75% -$320K ﹤0.01% 5632
2021
Q4 		$536K Sell
22,507
-23,474
-51% -$652K ﹤0.01% 4383
2021
Q3 		$1.42M Buy
45,981
+7,148
+18% +$216K ﹤0.01% 3371
2021
Q2 		$1.24M Buy
38,833
+15,684
+68% +$473K ﹤0.01% 3480
2021
Q1 		$693K Buy
23,149
+4,015
+21% +$131K ﹤0.01% 3905
2020
Q4 		$607K Sell
19,134
-139
-0.7% -$4.17K ﹤0.01% 3967
2020
Q3 		$529K Sell
19,273
-3,661
-16% -$97.9K ﹤0.01% 3801
2020
Q2 		$621K Sell
22,934
-3,129
-12% -$76.8K ﹤0.01% 3595
2020
Q1 		$510K Sell
26,063
-5,710
-18% -$123K ﹤0.01% 3596
2019
Q4 		$745K Buy
31,773
+721
+2% +$15.3K ﹤0.01% 3689
2019
Q3 		$583K Buy
31,052
+5,547
+22% +$113K ﹤0.01% 3740
2019
Q2 		$539K Buy
25,505
+17,238
+209% +$355K ﹤0.01% 3809
2019
Q1 		$174K Sell
8,267
-2,173
-21% -$45.6K ﹤0.01% 4439
2018
Q4 		$197K Sell
10,440
-18,384
-64% -$383K ﹤0.01% 4359
2018
Q3 		$716K Buy
28,824
+3,427
+13% +$84.2K ﹤0.01% 3640
2018
Q2 		$613K Buy
25,397
+3,961
+18% +$107K ﹤0.01% 3634
2018
Q1 		$623K Buy
21,436
+9,651
+82% +$274K ﹤0.01% 3543
2017
Q4 		$280K Sell
11,785
-1,530
-11% -$38.7K ﹤0.01% 4213
2017
Q3 		$360K Sell
13,315
-10,100
-43% -$246K ﹤0.01% 4063
2017
Q2 		$540K Sell
23,415
-1,550
-6% -$35.1K ﹤0.01% 3611
2017
Q1 		$606K Buy
24,965
+10,632
+74% +$245K ﹤0.01% 3486
2016
Q4 		$305K Buy
14,333
+661
+5% +$15.2K ﹤0.01% 4190
2016
Q3 		$353K Buy
13,672
+2,790
+26% +$68.8K ﹤0.01% 4004
2016
Q2 		$247K Buy
10,882
+3,375
+45% +$77.1K ﹤0.01% 4251
2016
Q1 		$163K Buy
7,507
+7,257
+2,903% +$155K ﹤0.01% 4491
2015
Q4 		$7K Buy
+250
New +$7.19K ﹤0.01% 6063

Other funds holding CNCR

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada's CNCR Position: Q2 2025 in Review

Royal Bank of Canada sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 82 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in CNCR in Q4 2015 and held it in 38 quarters. The position peaked at $1.42M in Q3 2021. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.

  • Royal Bank of Canada reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 82 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $1K.
  • Royal Bank of Canada first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and held it in 38 quarters.
  • Royal Bank of Canada's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1.42M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.

Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.